Home
Solutions
Products
Pricing
Resources
Request Demo
Start Free
Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo
StateStorm

Weekly Updates

LegiStorm is constantly adding new information on the people, places and reports in our database. In the past week, LegiStorm added:

  • 652 new people
  • 153 new organizations
  • 678 new photos
  • 1574 job history records for people in our database
  • 671 education records for people in our database
  • 1769 contact addresses, emails and URLs (LinkedIn, Facebook, etc.)
  • 5 new people through the revolving door
  • 187 new policy reports
  • 30 new trips to our privately funded travel database
  • 148 new personal financial disclosures
  • 15836 new press releases
  • 8 new town halls
  • 74 new hearings

Caught Our Eye Rss

» More from Caught Our Eye
» More from our DevBlog

European Union Drug Approval: Overview of New European Medicines Evaluation Agency and Approval Process

  Premium   Download PDF Now (25 pages)
Report Type Reports and Testimonies
Report Date April 5, 1996
Report No. HEHS-96-71
Subject
Summary:

With a population of 370 million, the European Union (EU) represents a consumer base that is one-third larger than that of the United States. Moreover, the EU leads the world in the consumption of pharmaceutical products--nearly $83 billion worth in 1992. The EU recently changed its drug approval procedures and created a new agency--the European Medicines Evaluation Agency--to approve drugs more quickly and efficiently. Advocates of reforming the Food and Drug Administration (FDA) have suggested that the new European model may provide helpful lessons for improving the timeliness of FDA drug approvals. This report (1) determines how the EU now reviews and approves new drug applications and (2) explains why the European Medicines Evaluation Agency was established, how it operates, and how it is financed. GAO notes that because the EU system has been up and running for only a year, it is too soon to know whether it will enable drug companies to more quickly market their products throughout Europe.

« Return to search Government Accountability Office reports

HomeAbout Us Contact UsPrivacy PolicyTerms of UseJoin Us
© LegiStorm
LegiStorm
2101 L St. NW, Suite 300
Washington, DC 20037
(202) 360-4172 / congress@legistorm.com